Status | Study |
Recruiting |
Study Name: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 Condition: Indolent Systemic Mastocytosis Date: 2016-06-16 Interventions: Drug: AK002 |
Recruiting |
Study Name: A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Condition: Gastrointestinal Stromal Tumors Aggressive Systemic Mastocytosis Date: 2015-10-05 Interventions: Drug: DCC-2618 10 mg and 50 mg formulated tablets |
Recruiting |
Study Name: Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Condition: Aggressive Systemic Mastocytosis Systemic Date: 2015-09-15 Interventions: Drug: BLU-285 |
Completed |
Study Name: Treatment of Indolent Systemic Mastocytosis With PA101 Condition: Mastocytosis Systemic Mastocytosis Date: 2015-06-19 Interventions: Drug: PA101 40 mg PA101 admini |
Recruiting |
Study Name: Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2015-05-05 Interventions: Procedure: Mastocytosis diagnosis Some samples will be extracted from bone marrow aspirate and periphera |
Recruiting |
Study Name: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Condition: Aggressive Systemic Mastocytosis Mast Cell Leukemia Date: 2015-03-24 Interventions: Drug: Ibrutinib Given PO |
Completed |
Study Name: Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Condition: Aggressive Systemic Mastocytosis (ASM) SM w Assoc Clonal Hema N Date: 2015-02-26 Interventions: Other: Interview Single interview lasting approximately one hour |
Recruiting |
Study Name: SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) Condition: Myelofibrosis Chronic Myelomonocytic Leukemia Advanced Date: 2014-10-10 Interventions: Drug: SL-401 |
Recruiting |
Study Name: Midostaurin in Indolent Systemic Mastocytosis Condition: Indolent Systemic Mastocytosis Date: 2013-08-07 Interventions: Drug: Midostaurin, Midostaurin, twice daily 100 mg orally, continuously for 6 months |
Recruiting |
Study Name: Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Condition: Aggressive Systemic Mastocytosis Mast Cell Leukemia Date: 2013-03-05 Interventions: Drug: brentuximab vedotin Brentuximab vedotin is an antibody with a covalently attached toxin. The antib |